Anti-inflammatory treatment in schizophrenia

@article{Mller2013AntiinflammatoryTI,
  title={Anti-inflammatory treatment in schizophrenia},
  author={Norbert M{\"u}ller and Aye Mu Myint and Daniela Krause and Elif Weidinger and Markus J. Schwarz},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2013},
  volume={42},
  pages={146-153}
}
Antipsychotics, which act predominantly as dopamine D2 receptor antagonists, have several shortcomings. The exact pathophysiological mechanism leading to dopaminergic dysfunction in schizophrenia is still unclear, but inflammation has been postulated to be a key player in the pathophysiology of the disorder. A dysfunction in activation of the type 1 immune response seems to be associated with an imbalance in tryptophan/kynurenine metabolism; the degrading enzymes involved in this metabolism are… Expand
Inflammation in schizophrenia: A question of balance
TLDR
This review focuses on the interactions between inflammation and O&NS, their damaging consequences for brain cells in schizophrenia, the possible origins of inflammation and increased O& NS in the disorder, and current pharmacological strategies to deal with these processes. Expand
Interleukin-6 in Schizophrenia—Is There a Therapeutic Relevance?
TLDR
The IL-6 plays significant role in disease genesis and progression, so the use of specific inhibitors may not only be beneficial for exacerbation and alleviation of positive symptoms, but may attenuate cognitive impairment in patients with schizophrenia. Expand
Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia.
TLDR
Clinicians should stay up to date with the literature, obtain detailed immunological histories, and review the risk-benefit ratio of adding available immune modulating agents to standard therapies, to provide optimal and state-of-the-art care to patients. Expand
The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia
TLDR
Findings support the involvement of an active cross-talk between the dopaminergic and immune systems in the physiopathology of schizophrenia and suggest alterations in dopamine levels associated to schizophrenia might affect inflammatory response of immune cells and consequently some behavioral functions. Expand
Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia
TLDR
Evidence for the role of prenatal infection, both epidemiological and experimental, is excellently reviewed by UrsMeyer (2013–this issue) who has published extensively in this area. Expand
Effects of inflammation on the kynurenine pathway in schizophrenia — a systematic review
TLDR
This systematic review aims to collect reliable recent findings within the last decade supporting a theory that several tryptophan/kynurenine pathway metabolites are produced which can underlie different psychotic and cognitive symptoms via neurotransmission modulation and does not find a significant correlation between CRP, IFN-γ, and the kynuranine pathway in schizophrenia. Expand
Peripheral Biomarkers for First-Episode Psychosis—Opportunities from the Neuroinflammatory Hypothesis of Schizophrenia
TLDR
Peripheral molecules stemming from brain inflammation might provide insightful biomarkers of schizophrenia, as early as FEP or even prodromal phases, although more time- and clinically-adjusted studies are essential for their validation. Expand
Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia
TLDR
Further evidence is provided for the role of inflammation in a subgroup of patients with schizophrenia and a molecular mechanism through which inflammation could lead to schizophrenia is suggested. Expand
Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings
TLDR
Patients with SCZ and their siblings exhibited similar clinical features and TRP metabolite levels suggesting that TRP-KYN dysregulation may be an inherited component of the disease putatively conferring increased risk to schizophrenia. Expand
Transcriptomic signatures of schizophrenia revealed by dopamine perturbation in an ex vivo model
TLDR
A cell perturbation approach and measured transcriptomic profiles by RNAseq to study the effect of DA exposure on transcription in B-cell transformed lymphoblastoid cell lines (LCLs) from 514 SZ cases and 690 controls found that DA had widespread effects on both cell growth and gene expression in LCLs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 132 REFERENCES
Immunological treatment options for schizophrenia.
TLDR
Growing evidence from clinical studies with COX-2 inhibitors points to favourable effects of anti-inflammatory therapy in schizophrenia, in particular in an early stage of the disorder. Expand
Inflammation in schizophrenia.
TLDR
Growing evidence from clinical studies with COX-2 inhibitors points to favorable effects of anti-inflammatory therapy in schizophrenia, in particular in an early stage of the disorder. Expand
Immune System and Schizophrenia.
TLDR
In schizophrenia a blunted type-1 immune response seems to be associated with a dysbalance in the activation of the enzyme indoleamine 2,3-dioxygenase and in the tryptophan - kynurenine metabolism resulting in increased production of kynurenic acid in schizophrenia. Expand
The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view.
TLDR
The immune-mediated glutamatergic-dopaminergic dysregulation may lead to the clinical symptoms of schizophrenia and the use of antiinflammatory cyclooxygenase-2 inhibitors, which also are able to directly decrease KYN-A, are discussed. Expand
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
TLDR
A hypothesis integrating current concepts of neurotransmission and hypothalamus–pituitary–adrenal (HPA) axis dysregulation with findings on immunological alterations and alterations in brain morphology in MD is presented. Expand
Kynurenic acid and schizophrenia.
TLDR
The present study suggests a contribution of KYNA in the pathogenesis of schizophrenia and link the dopamine hypothesis of schizophrenia together with the idea of a deficiency of glutamate function in this disease. Expand
Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review
TLDR
These findings provide the first evidence of establishment of an inflammatory syndrome in schizophrenia, which refutes the current hypothesis of a Th2 slant. Expand
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
TLDR
The present study suggests that focal neuroinflammation may play an important role in schizophrenia during psychosis. Expand
COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy
TLDR
The fact that treatment with an immunomodulatory drug shows beneficial effects on the symptomatology of schizophrenia indicates that immune dysfunction in schizophrenia is not just an epiphenomenon, but related to the pathomechanism of the disorder. Expand
Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder
TLDR
Evidence is found of increased TDO2 activity in schizophrenia at three different levels of regulation: mRNA, protein, and metabolic product, and the increase in TDO 2 protein in the major depression group was not associated with an increase in kynurenine concentration. Expand
...
1
2
3
4
5
...